Two recent studies published in The American Journal of Human Genetics provide compelling evidence for the potential of genome-based newborn screening to improve infant health outcomes. Leveraging advanced genomic technologies, these studies introduce BeginNGS, a novel platform designed to enable early diagnosis and treatment of genetic diseases—addressing a longstanding challenge in neonatal care.
A New Approach to Newborn Screening
The BeginNGS platform combines genome sequencing with artificial intelligence to provide actionable diagnostic results within two weeks of birth. This system aims to streamline the detection of hundreds of severe genetic conditions, many of which are preventable or treatable if identified early. The technology addresses two major hurdles of genome-based screening: high costs and false positives, which have previously limited its widespread use.
BeginNGS achieves a 97% reduction in false positives using a computational method inspired by
evolutionary biology. The research team analyzed genomic data from nearly half a million middle-aged and elderly individuals in the UK Biobank and the Mexico City Prospective Study. They identified DNA variants unlikely to cause severe childhood diseases—variants typically absent in individuals with advanced age due to a process called purifying hyperselection. This approach minimizes the risk of misdiagnosis while maintaining over 99% sensitivity compared to the gold standard diagnostic genome sequencing.
Transforming Diagnostics with Practical Solutions
The platform also incorporates Genome to Treatment (GTRx), a clinical guidance system designed to assist physicians in interpreting results and developing treatment plans for rare genetic disorders. This tool is particularly valuable in addressing the challenges faced by general practitioners who may encounter these conditions only rarely.
In a retrospective analysis of over 3,000 children suspected of genetic disorders, BeginNGS demonstrated a significant advantage, identifying conditions 121 days earlier than traditional diagnostic methods. For infants who passed away before diagnosis, 1 in 13 might have benefited from earlier testing with BeginNGS.
TileDB, a database technology partner for BeginNGS, contributed to the development of a federated query system that allows for secure genomic data analysis without transferring sensitive information. Stavros Papadopoulos, CEO of TileDB, emphasized the significance of global collaboration. “"By connecting genetic information across international databases, we significantly enhance our ability to identify and understand rare diseases,” he said. This capability has the potential to expand BeginNGS’s reach to genomic biobanks worldwide.
Clinical Trials Confirm Effectiveness
The second study evaluated BeginNGS in a NICU pilot trial at Rady Children’s Hospital-San Diego, involving 120 newborns. Unlike traditional newborn screening, BeginNGS demonstrated no false positives while identifying actionable results in 1 out of every 24 babies tested. The platform outperformed existing state-mandated screenings with a higher true positive rate and a lower false positive rate.
Stephen Kingsmore, president and CEO of Rady Children’s Institute for Genomic Medicine, highlighted the unexpected findings of a neonatal intensive care unit (NICU) pilot trial. “Nearly 30 percent of NICU babies who weren’t considered to need genome sequencing actually had genetic diseases,” Kingsmore said. This suggests a broader application of genome-based screening for all NICU admissions, not just those suspected of genetic conditions.
Toward Broader Implementation
BeginNGS has already demonstrated the feasibility of scaling up to screen the 3.7 million babies born annually in the United States. The ongoing multicenter clinical trial aims to compare the platform directly with current newborn screening methods. With proven effectiveness in the NICU setting, BeginNGS is poised to expand its diagnostic coverage from 412 severe genetic conditions to over 2,000 actionable disorders.
Tom DeFay, vice chair of the BeginNGS Consortium, expressed optimism about the findings. “Genome-based newborn screening has the potential to transform health outcomes for children with certain rare diseases by accelerating their time to diagnosis and proper care,” he said.
A New Approach to Newborn Screening
The BeginNGS platform combines genome sequencing with artificial intelligence to provide actionable diagnostic results within two weeks of birth. This system aims to streamline the detection of hundreds of severe genetic conditions, many of which are preventable or treatable if identified early. The technology addresses two major hurdles of genome-based screening: high costs and false positives, which have previously limited its widespread use.
BeginNGS achieves a 97% reduction in false positives using a computational method inspired by
evolutionary biology. The research team analyzed genomic data from nearly half a million middle-aged and elderly individuals in the UK Biobank and the Mexico City Prospective Study. They identified DNA variants unlikely to cause severe childhood diseases—variants typically absent in individuals with advanced age due to a process called purifying hyperselection. This approach minimizes the risk of misdiagnosis while maintaining over 99% sensitivity compared to the gold standard diagnostic genome sequencing.
Transforming Diagnostics with Practical Solutions
The platform also incorporates Genome to Treatment (GTRx), a clinical guidance system designed to assist physicians in interpreting results and developing treatment plans for rare genetic disorders. This tool is particularly valuable in addressing the challenges faced by general practitioners who may encounter these conditions only rarely.
In a retrospective analysis of over 3,000 children suspected of genetic disorders, BeginNGS demonstrated a significant advantage, identifying conditions 121 days earlier than traditional diagnostic methods. For infants who passed away before diagnosis, 1 in 13 might have benefited from earlier testing with BeginNGS.
TileDB, a database technology partner for BeginNGS, contributed to the development of a federated query system that allows for secure genomic data analysis without transferring sensitive information. Stavros Papadopoulos, CEO of TileDB, emphasized the significance of global collaboration. “"By connecting genetic information across international databases, we significantly enhance our ability to identify and understand rare diseases,” he said. This capability has the potential to expand BeginNGS’s reach to genomic biobanks worldwide.
Clinical Trials Confirm Effectiveness
The second study evaluated BeginNGS in a NICU pilot trial at Rady Children’s Hospital-San Diego, involving 120 newborns. Unlike traditional newborn screening, BeginNGS demonstrated no false positives while identifying actionable results in 1 out of every 24 babies tested. The platform outperformed existing state-mandated screenings with a higher true positive rate and a lower false positive rate.
Stephen Kingsmore, president and CEO of Rady Children’s Institute for Genomic Medicine, highlighted the unexpected findings of a neonatal intensive care unit (NICU) pilot trial. “Nearly 30 percent of NICU babies who weren’t considered to need genome sequencing actually had genetic diseases,” Kingsmore said. This suggests a broader application of genome-based screening for all NICU admissions, not just those suspected of genetic conditions.
Toward Broader Implementation
BeginNGS has already demonstrated the feasibility of scaling up to screen the 3.7 million babies born annually in the United States. The ongoing multicenter clinical trial aims to compare the platform directly with current newborn screening methods. With proven effectiveness in the NICU setting, BeginNGS is poised to expand its diagnostic coverage from 412 severe genetic conditions to over 2,000 actionable disorders.
Tom DeFay, vice chair of the BeginNGS Consortium, expressed optimism about the findings. “Genome-based newborn screening has the potential to transform health outcomes for children with certain rare diseases by accelerating their time to diagnosis and proper care,” he said.